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In tr o d u c tio n
The high cost of essential medicines is a big problem. Recently, here in the 
United States where I live, social media and even lawmakers exploded in 
anger over a 400 percent-plus increase in the lifesaving allergy medicine 
EpiPen. Similar outrage occurred when a young pharmaceutical corpora­
tion chief executive officer (CEO) increased the price of a critical toxo­
plasmosis drug by more than 5,000 percent overnight—just because he 
could. A hundred-plus cancer physicians took to the pages of the pres­
tigious journal Mayo Clinic Proceedings to write an impassioned article 
decrying the greed of the pharmaceutical industry. These physicians com­
plained that drug companies were setting medicine prices so high that one 
out of every five of their patients was unable to fill his or her prescrip­
tions. In response to all these incidents and the popular outrage they have 
inspired, patients, caregivers, and politicians from both major political 
parties have leveled charges of medicine price gouging against the phar­
maceutical companies.
2 Introduction
Even for those of us who are fortunate enough to not be poor and to 
have health insurance, the cost of medicines has a big impact. The cost of 
medicines drains the budgets of our governments, and barriers to access­
ing medicines lead to more expensive health care treatments and illnesses 
that drag down our economy. Polls show that three-quarters of Americans 
believe that drug costs are unreasonable and that those prices reflect the 
greed of drug companies.1
For the poor and the uninsured, access to medicines is a matter of life 
and death. Millions of people need medicines that are priced at levels they 
simply cannot afford. These suffering patients face a real problem: their 
desperate need for affordable drugs clashes with the core business model 
of a powerful industry.
On one side of that clash are multinational pharmaceutical corpora­
tions, which make up one of the most profitable and politically influential 
industries in history. That industry is determined to protect monopoly 
prices on patented medicines. On the other side of the clash are the sick 
and the poor, joined by advocates scattered across the globe in small, usu­
ally underfunded organizations. At first glance, it doesn’t seem like a fair 
fight. But patients and medicine activists have won before.
In the midst of the HIV/AIDS crisis of the late 1990s and early 2000s, 
millions of people were dying because they could not afford lifesaving 
drugs. Patients and activists who wanted to change this tragic reality faced 
fierce resistance from a formidable collaboration between Big Pharma and 
the U.S. government. The multinational corporations and the world’s 
economic superpower were intent on preserving the high monopoly price 
tags on patented AIDS drugs and to block affordable generic alterna­
tives. But the activists working in the United States, sub-Saharan Africa, 
South America, and Asia pushed back hard. They flooded the streets with 
protests, filed lawsuits, and mercilessly heckled the drug companies and 
politicians. They made a moral claim that medicine should be for peo­
ple, not profits, and that there is a fundamental human right to essential 
medicines. That message resonated across the world, and these activists 
eventually triumphed, reducing the costs of the medicines by as much as 
99 percent; setting the stage for a massive global distribution of the drugs. 
Millions of lives were saved.
But the fruits of that victory, the widespread availability of cheap HIV/ 
AIDS medicines, is an exception to the rule. Whereas millions once died
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of untreated HIV/AIDS, now millions die from untreated cancer. Chil­
dren die because their families cannot afford vaccinations. The episodic 
drug pricing outrages, such as the reaction to the EpiPen price hike or the 
overreach of the “Pharma Bro” Martin Shkreli, have not led to systemic 
change.
So the same activists who pushed for HIV/AIDS treatment, accompa­
nied by a new generation of advocates, are trying to produce a sequel 
with an even more ambitious script than they followed at the turn of the 
century. Their aim is to make all essential drugs accessible by reclaiming 
medicines as a public good instead of a profit-making commodity.
One of these activists’ biggest challenges is that the terms of their fight 
can seem complex and confusing. Too often, calls for reform get bogged 
down in technical intellectual property terms—compulsory licensing, data 
exclusivity, and patent linkage—and confusing acronyms for international 
trade agreements—TRIPS (Trade-Related Aspects of Intellectual Prop­
erty Rights Agreement), TRIPS-Plus, and TPP (Trans-Pacific Partnership 
Agreement). This thicket of complexity provides cover for corporations 
that rely on the for-profit medicine model and are determined to protect 
the status quo. As one leading medicine activist admitted to me, “The 
problem we have is that there are only a handful of people in the world 
who know what we are taking about.”2
It does not have to be this way. My aim in this book is to help clear 
away for you the thicket of jargon that surrounds this crisis so that you 
can effectively argue for a complete shift in the global approach to de­
veloping and providing essential medicines. This shift would restore the 
longtime historical recognition that medicines are a public good, reflecting 
the global consensus that access to essential medicines is a human right.
Because every cure starts with an accurate diagnosis, in this book I ex­
plain how and why the current medicines system is dysfunctional and cor­
rupt. We all want both affordable medicines and innovation in research 
and development, so I explain the proven approaches to accomplishing 
that balance. Most of us reject the status quo of corporations making 
record-breaking profits on medicines that are priced out of the range of 
the sick and the dying, so I set out the moral and rights-based foundation 
of the case for universal access to medicines. Finally, if you want to take 
action and speak out for access to medicines—and I sincerely hope you 
do—the conclusion to this book is devoted to helping you get started.
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4 Introduction
I chose to structure the book around twenty-two arguments for why 
we must reform our medicines system and how to do so. Each chapter 
contains a single argument. I encourage you to skim the table of contents 
both before you read the book and afterward. When you need to refer to 
a particular issue connected with access to medicines—such as the fruits 
of government-funded medicines research being handed over to corpora­
tions for profit-making (chapters 14 and 15)—the table of contents will 
guide you.
This book is a short one. At the same time, all the points I make here 
are thoroughly sourced. Many, many researchers and activists have writ­
ten important detailed analyses of these issues; so you will see hundreds 
of notes to prior work that backs up the arguments I make here. I have 
placed those sources in endnotes at the end of the book so you can read 
the main text without interruption, if you wish.
My hope is that this book will serve as a primer for all who are con­
cerned about access to medicines. My hope is also that this book will 
buttress the analyses of researchers and the arguments of activists. Most 
important, my hope is that this book will help you become informed and 
prepared to play your role in the life and death struggle for access to 
medicines.
1Peo ple  Everyw here A re Str u g g lin g  
to G et th e  M e d ic in e s  Th ey  N eed
Hannah Lyon was just twenty-six years old when she was diagnosed with 
advanced cervical cancer.1 To her first set of doctors, Lyon’s best-case sce­
nario was chemotherapy and radiation that would extend her life for only 
a few years. Desperate for a more promising approach, Lyon found a clin­
ical trial at the National Institutes of Health (NIH). There she received 
cutting-edge immunotherapy, in which her immune cells were removed, 
genetically modified, and reinserted into her bloodstream. Since the treat­
ment, Lyon’s tumors have shrunk more than 80 percent.
But Lyon soon realized that most cancer patients are not so fortunate. 
She saw fellow patients struggling to pay for the medicines that were their 
only hope for survival. Lyon learned that others had simply been unable 
to pay and therefore had died from highly treatable cancers.
Lyon had heard the pharmaceutical industry argument that the high 
medicine prices are necessary to fund drug research. But, then, during 
her own treatment at the government-funded NIH, Lyon noticed some­
thing. “When I had my cell infusion, there were pharmaceutical reps in the
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room, because they want to take that treatment and offer it commercially. 
So this whole argument that pharma corporations need long monopoly 
periods to pay for the research . . . well, they are not even the ones doing 
the research! They did not develop that drug. They are just going to take 
that drug and charge people tons of money.”
Lyon began reading about medicine patents and the international 
trade agreements that protect them. She learned how government-funded 
research, not corporate investment, is the most important driver in creat­
ing new medicines. She discovered that our profit-driven medicines sys­
tem is neglecting development of lifesaving medicines in favor of lucrative 
drugs to address hair loss or sexual performance.
Then Lyon happened to see a television interview with Zahara Heck- 
scher, a breast cancer patient who had been arrested while protesting at 
the Trans-Pacific Partnership Agreement (TPP) negotiations in Atlanta in 
October 2015. The TPP was the latest in a series of trade deals that pro­
posed to lock in corporate medicine monopolies and lock out suffering 
patients from the treatment they need. As we learn in chapter 18, the TPP 
promised to be particularly damaging to patients who need the kind of 
cutting-edge treatment that both Hannah Lyon and Zahara Heckscher 
received. So Heckscher had decided to use her status as a cancer patient to 
raise awareness of the dysfunctional medicines system. “That is amazing,” 
Lyon thought. Then she thought some more. “J could do that.”
So, on World Cancer Day in 2016, Lyon joined Heckscher in a sit-in 
at the Washington, DC, headquarters of the Pharmaceutical Researchers 
and Manufacturers Association (PhRMA). The organization is a coalition 
of pharmaceutical corporations that spends billions of dollars in politi­
cal lobbying and campaign contributions, all to protect medicine patent 
monopolies—and the record-setting profits those monopolies provide. 
Wearing matching black t-shirts with white lettering that read, “ I am a 
cancer patient. No TPP death sentence,” Lyon and Heckscher blocked the 
building entrance. “We will not leave until PhRMA stops pushing extreme 
monopolies through the Trans-Pacific Partnership,” they said.
Outside, demonstrators from a World Cancer Day action coordinated 
by the advocacy group Public Citizen could see Lyon and Heckscher lock 
arms. The crowd got excited and increased the volume on its chants: 
“ Shame on PhRMA!” “TPP no!” By now, someone was filming, so Lyon 
and Heckscher looked at the camera. “We have a message for Congress
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on World Cancer Day. Listen to the cancer patients who will suffer if the 
TPP is approved.”2 They were arrested and charged with unlawful entry.
Soon after, Lyon and Heckscher formed a new organization, Cancer 
Families for Affordable Medicine (CancerFAM).4 CancerFAM is devoted, 
first, to stopping the TPP and, then, to fixing the other pharma-pushed 
trade deals and laws that elevate profits over patients. Lyon says advo­
cacy has empowered her and transformed her own cancer story from one 
of weakness to one of strength. She believes that others can follow the 
same path.
Sarah Jackson does not have cancer, but she faces the same challenge that 
many of Hannah Lyon’s fellow cancer patients do. The mother of six chil­
dren, Sarah Jackson has hepatitis C (hep C), a blood-borne virus that can 
inflame and scar the liver, damaging its ability to filter toxins. Sometimes 
hep C causes cancer and liver failure. Sarah Jackson’s physician has pre­
scribed her a medicine to treat her disease. The medicine is almost certain 
to cure her before the hepatitis virus can cause irreparable liver damage or 
trigger liver cancer. The medicine would also prevent her from spreading 
the virus to others, including any future children she may give birth to.4
Sarah Jackson does not live in an impoverished country. She lives in 
Fort Wayne, Indiana, in the United States, one of the wealthiest countries 
in the world and the country that spends far and away the most on health 
care.5 Nevertheless, Sarah Jackson cannot get access to the medicine she 
needs.
The medicine that Sarah Jackson’s physician has prescribed her is 
sofosbuvir, a new hepatitis C drug that is controlled under patent by the 
U.S.-based pharmaceutical company Gilead. Gilead markets sofosbuvir 
under the names Sovaldi and Harvoni. The company has taken advantage 
of its monopoly patent power to price Sovaldi and Harvoni at costs that 
approach $1,000 per pill. The recommended twelve-week regimen cost as 
much as $100,000.6
That price is so forbidding that U.S. private insurance companies and 
the U.S. Veterans Administration have refused to approve the use of the drug 
for some patients, even when clinical treatment guidelines called for it.7 
A 2015 study published in the journal Annals of Internal Medicine showed 
that three-quarters of state Medicaid programs block many patients from 
receiving sofosbuvir despite their doctor’s insisting they need it.x A U.S.
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Senate investigation concluded that only about 2 percent of Medicaid 
patients with hepatitis C were being treated with sofosbuvir.9 And the 
problem is not limited to the United States. A World Health Organization 
study showed the price of the drug exceeded annual per capita income lev­
els in many countries with high hepatitis C infection rates. For example, 
in Poland, Portugal, Slovakia, and Turkey, a course of sofosbuvir costs at 
least two years of average annual wages.10
One of the U.S. state programs that rations the use of sofosbuvir is 
in Indiana, where Sarah Jackson is enrolled in Medicaid. Indiana offi­
cials refuse to pay for the medicine for hepatitis C patients until the 
patients’ disease has progressed to the point of causing advanced liver 
damage. Sarah Jackson has not endured that much damage yet, so her 
doctor’s application to have the medicine provided was denied. The doc­
tor appealed to higher-ups in the program, but to no avail.
Then the doctor put Jackson in touch with public interest lawyers. 
With the lawyers’ help, she has filed suit on behalf of thousands of others 
in Indiana who were in the same situation, asking for Medicaid to provide 
the medicine when their physicians say they need it. Sarah Jackson had 
never intended to become an activist. But, like Hannah Lyon, her illness 
pushed her in that direction. “There’s nowhere else to go,” she says. “The 
doctor tried and now I have no other place to turn.” 11
Rationing plans such as the one in Indiana have angered patient advo­
cacy groups and veterans’ organizations, and they have caused a passion­
ate but less public backlash from treating physicians.12 On the other side, 
the administrators of the government health care systems are in a tight 
spot. The state of Kentucky spent 7 percent of its total 2014 Medicaid 
budget, over $50 million, solely on Gilead drugs to treat just 861 hepati­
tis C patients.13 The Veterans Administration was reported to have spent 
$1 billion on the drugs in the 2016 fiscal year.14 When a reporter asked 
him to comment on Sarah Jackson’s situation, Matt Salo, director of the 
National Association of Medicaid Directors said, “With the price of hepa­
titis C drugs, it is just not feasible to provide it to everyone.” 15
As that comment suggests, Sarah Jackson is far from alone. An esti­
mated 2.7 million people in the United States are infected with hepatitis 
C, and its complications cause 15,000 U.S. deaths each year.16 Globally, 
150 million are infected and a half-million die from hepatitis C-related 
causes annually.17 The World Health Organization calls the disease a
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“viral time bomb.” 18 In the United States, a recent spike in intravenous 
drug use, chiefly among young people, has triggered a corresponding burst 
of new hepatitis C infections.19 The rate of infection among U.S. military 
veterans is significantly higher than in the general population, partly due 
to exposure to blood in combat and training and to transfusions con­
ducted before routine blood screenings began in 1992. According to the 
Veterans Administration, more than 200,000 U.S. military veterans are 
likely to have hepatitis C.2()
The good news for those diagnosed with hepatitis C is that sofosbuvir 
is a remarkably effective treatment, combining with other drugs to cure 
the infection in more than 90 percent of patients.21 The bad news is that 
Gilead has responded to the high demand for this wonder drug by setting 
a take-it-or-leave-it price that is 1,000 times greater than the company’s 
manufacturing costs.22 Advocates and even some government agencies 
have leveled accusations of price gouging, pointing out that the cost of a 
full regimen of sofosbuvir in Egypt and India is just $900, a 99 percent 
reduction from the U.S. price.23 The Nobel Peace Prize-winning health 
care and advocacy organization Medecins Sans Frontieres/Doctors With­
out Borders (MSF), estimates that the probable generic cost of the drug 
regimen would be under $200, or about 1/500 of the price currently 
charged to U.S. patients.24
The response by Gilead to its critics is the boilerplate argument from 
patent-holding pharmaceutical corporations: high drug prices are neces­
sary to support research and development efforts.25 But it turns out that 
government funding was the critical component in the development of 
sofosbuvir, not corporate investment.26 As we see in chapter 14, this is a 
common phenomenon in drug research, with major advancements reliably 
supported by the same taxpayers who are later required to pay high prices 
set by corporations that possess government-granted patent monopolies.27 
In the business of medicines, the new product risks are socialized, but 
profits are privatized.
2Th e  Un ited  States 
H as a D rug  Pr o b lem
The corporation Gilead owns the patent on sofosbuvir, the medicine that 
Sarah Jackson and millions of others with hepatitis C need. That pat­
ent awards the corporation a monopoly that allows it to set the price 
of sofosbuvir at whatever level the corporation believes the market will 
bear. Gilead has bet that the market will bear an astronomical price for 
a desperately needed medicine, and that bet has paid off, particularly in 
the United States, where aggressive pharmaceutical industry lobbying has 
blocked overall price regulation and even the ability of the government 
to negotiate the prices of the drugs it purchases itself.1 Gilead collected 
$12 billion in hepatitis C drug sales revenue in 2014, at least half of it paid 
by U.S. government agencies.2 That kind of income allows the company to 
pay John Martin, its CEO, as much as $180 million per year.3
The crisis caused by monopoly drug pricing is not limited to hepatitis 
C patients such as Sarah Jackson.4 There are many other examples of 
essential medicines being priced out of the reach of patients in the United 
States and in other wealthy nations. For example, spending on medicine
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for diabetes, a disease diagnosed in 29 million Americans, is higher per 
patient than any other traditional drug class, in part because more than 
half of diabetes prescriptions filled are for patented drugs.5 The cost for 
insulin lispro, marketed by the pharmaceutical corporation Eli Lilly under 
the name Humalog, increased by 325 percent from 2010 to 2015.6 There 
were only two other insulin manufacturers in the United States, Sanofi 
and Novo Nordisk, and they also hiked their prices over 100 percent in 
that time span. There is no generic form of insulin, and the lack of price 
regulation of medicines in the United States keeps prices up to six times 
higher than in other developed nations, a situation that U.S. Senator Jon 
Tester (D-MT) labeled “price gouging, plain and simple.” 7
Not surprisingly, U.S. physicians report routinely seeing patients whose 
lives are at risk because they cannot afford to use the prescribed amount 
of insulin.8 A 2017 lawsuit alleging price collusion among the insulin 
manufacturers includes reports of U.S. patients injecting expired insulin, 
starving themselves to control their blood sugars, and intentionally allow­
ing themselves to slip into dangerous states of diabetic ketoacidosis so 
they could get free insulin samples from hospital emergency rooms.9 In 
low-income countries, the situation is even more dire. A diabetes patient 
advocate reported a 2017 conversation with a physician in Cameroon, 
who shared the story of a young patient’s father happily delivering news. 
“Did you hear? Isabelle died!” the father said with a smile. He was refer­
ring to his diabetic daughter (the name here is a pseudonym), whose need 
for insulin and equipment like syringes and blood sugar test strips had 
plunged the family into financial distress. “Now we are all able to eat 
enough, and the other children can get an education.” 10
In addition to insulin, similarly high costs are faced by U.S. patients 
in need of medicine to address heart disease, high cholesterol, and infec­
tions.11 Vaccines are priced so high that one-third of U.S. family physicians 
say they are considering ending their practice of offering vaccinations 
because they cannot afford to buy them and keep them in stock.12 In 2015, 
Turing Pharmaceuticals suddenly increased by 5,000 percent the price of 
its anti-infection drug Daraprim. Overnight, the price rose from $13.50 
to $750.00 per tablet, a spike that brought the annual cost of treatment to 
as much as a half million dollars.13 From 2007 to 2016, Mylan Pharma­
ceuticals hiked the price of the lifesaving anti-allergy medicine EpiPen by 
nearly 500 percent.14 Although the audacity of these price hikes generated
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instant outrage—the two 2016 major-party U.S. presidential candidates 
called the Daraprim spike “price gouging” (Hillary Clinton) and “ disgust­
ing” (Donald Trump)—they were just extreme examples of the common 
industry practice.15 From 2012 to 2015, list prices on medicines made by 
large pharmaceutical corporations rose by over 12 percent per year, far 
exceeding the less than 2 percent annual rate of inflation over that period 
and also far exceeding the increase in other health care costs,16 In 2015, 
drug prices in the United States rose by almost 16 percent.17
Those rising prices are a predictable result of the U.S. approach to medi­
cines, which includes a unique combination of huge government spending 
on medicines paired with no regulation of medicine prices (a combination 
I explore more fully in chapter 15).18 The result is an environment with no 
price restraints. “Medicare is a huge, guaranteed market,” one industry 
observer says. “So the (pharmaceutical) companies are saying, ‘Let ’er rip!' ” 14 
So it is not surprising that U.S. patients pay the highest prices for 
medicine in the world, a per capita cost of about $1,000 per year.’0 
Consider this:
•  A recent study showed that the median monthly price of branded can­
cer drugs in the United States was almost $8,700, compared with about 
$2,600 in the United Kingdom, $2,700 in Australia, and $3,200 in 
China.21
•  In the United States, medicines represent 10 percent of national spend­
ing on health and nearly 20 percent of spending in employer health in­
surance plans.22
•  Overall prescription drug spending in the United States is over $400 bil­
lion annually; global spending exceeds $1 trillion.25 Some European 
health systems, which unlike the U.S. Medicare program do negotiate 
drug prices, have even refused to pay for some high-cost medicines.24
Ultimately, these whopping U.S. medicine bills are paid by the tax­
payers who subsidize government health care programs such as Medicare 
and Medicaid. They are also paid by private health care systems, whose 
CEOs’ report that rising drug costs are undermining the finances of their 
companies.25 Increasingly, the costs incurred by those private companies 
are passed on to patients. Even when U.S. residents are covered by private 
insurance plans, those plans usually charge premiums and copayments,
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and do not cover costs until a deductible threshold is met. In the last 
decade, U.S. workers’ obligations for those health insurance premiums 
rose 83 percent and their deductibles rose 255 percent, with 2016 testi­
mony to a U.S. Senate committee identifying prescription drug prices as 
the biggest reason for those increases.26 One of the results of this crisis is 
that medical debt has become the single largest cause of bankruptcy in the 
United States.27
As Sarah Jackson can attest, for many patients, the high cost of medi­
cines simply means that a doctor’s prescription goes unfilled. In a 2015 
U.S. poll, 19 percent of respondents said they had recently not filled a 
prescription because they could not afford the price.28 Another survey 
reported that 50 million Americans each year skip taking prescribed med­
ication due to the cost.29 Predictably, there is a human price to be paid 
for missing medications: multiple studies have shown that persons who 
struggle to access prescribed drugs are at greater risk of heart attacks, 
strokes, and other life-threatening health emergencies.70
Even when patients do have adequate insurance coverage or can afford 
to pay out of pocket the cost of the medicine they need, they often discover 
that the medicine is still not available to them. In the United States, medi­
cine shortages are reported to be “ the new normal,” with regular gaps 
in the availability of essential antibiotics, cancer drugs, and anesthetics, 
among hundreds of other medicines.71 In 2013, 83 percent of U.S. cancer 
physicians reported not being able to provide a patient with the preferred 
chemotherapy at least once in the previous six months. One-third of those 
physicians reported having to delay treatment or exclude patients from 
the medicine altogether.72 Reports of medicine rationing have been reg­
istered in the treatment of leukemia, ovarian cancer, bladder cancer, and 
infections in need of antibiotics.77 Some U.S. physicians admit they delib­
erately avoid telling their patients that they are not getting the medicine 
they need.74
Like high prices, these shortages are the inevitable consequence of a 
medicine system built on a foundation that relies on the motivations of 
corporations seeking the highest possible profits. If pharmaceutical cor­
porations determine there is not sufficient money to be made producing 
a medicine, especially compared to other products that they can charge 
enormous mark-ups for, they have no incentive to make enough of the 
medicines that have lower profit margins. The shortages are also spurred
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on by the secretive, exclusive character of the patent system, which leads 
to a limited number of manufacturers of the needed drugs.35
Even if the medicines that are in shortage are potentially profitable 
to manufacture, “ intellectual property” rights often trump patient needs. 
For example, when the Cleveland Clinic responded to a shortage of a 
blood-vessel surgery drug by mixing up its own version in-house, the 
clinic physicians wanted to share the formula with their colleagues facing 
similar shortages in other hospitals. But they discovered they could not do 
so: the Cleveland Clinic had claimed exclusive rights to the combination.36
Sometimes drug shortages are the result of quality control issues in 
the medicine manufacturing process. But that problem too can be traced 
back to the for-profit nature of the industry because corporations see little 
urgency in fixing the manufacturing problem for a medicine that produces 
limited revenue. As a journalist who investigated drug shortages said, 
“Sometimes what happens is a [production] line goes down, something 
breaks down and a company, a producer looks at the margins and the 
economics and says ‘well, you know it’s not really worth the margins 
we’re getting on this drug in continuing the line—in putting the money in 
to fix it.’ So they let the drug go into shortage. And even if people need 
it—say it’s nitroglycerine which is critical in heart surgery—they just don’t 
produce it.” 37
Instead, for-profit pharmaceutical corporations inevitably focus their 
investments and their production capacity on medicines that provide a 
hefty profit. We have already read about one example: the hepatitis C 
medicine with a 500 percent mark-up (chapter 1). Not surprisingly, there 
have been no reported shortages of Sovaldi or Harvoni.
3M ill io n s  o f  Peo ple  
Are Dyin g  N e e d le ssly
Tobeka Daki lived with her two sons in the Mdanstane Township in the 
Eastern Cape province of South Africa. Her youngest son, Khanya, is 
eleven years old. She was a breast cancer patient, struggling with a partic­
ularly aggressive strain of the disease known as HER2.1
Trastuzumab is a medicine that is effective in treating HER2-positive 
breast cancer.2 Marketed under the brand name Herceptin by the phar­
maceutical company Roche, the medicine is so successful at improving 
survival rates for HER2 patients such as Tobeka that the World Health 
Organization has placed it on its “ Essential Medicines List,” an exclu­
sive category of drugs that are considered necessary to meet the minimum 
medicine needs for a basic health care system.3 The development of trastu- 
zumab was so impactful that the story was turned into a Lifetime TV 
movie, Living Proof, starring Harry Connick Jr. as the physician whose 
research helped show that the medicine would benefit cancer patients. 
Herceptin has become one of the best-selling prescription drugs in the 
world.4
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The cost to manufacture a year’s worth of trastuzumab, the recom­
mended length of treatment for a patient such as Tobeka, is about $176/ 
Yet that same amount of medicine is sold by Roche in South Africa at a price 
of about $34,000/ The company holds the South African patent for the 
medicine until 2033; this means that there are no competitors to push Roche 
to lower the price. Roche sells over $6 billion of the medicine each year.7
The $34,000 price tag for trastuzumab was far more than Tobeka could 
pay. The same goes for the vast majority of other HER2-positive breast 
cancer patients in South Africa, where the per capita income is $6,800/ 
Few private insurers cover the drug. The public-sector health care system 
so rarely provides trastuzumab that physicians in that system usually do 
not even tell their HER2 patients about the existence of the drug/
When I spoke with Tobeka in March 2016, she explained that her can­
cer had recently spread to her spine, so she had officially reached the Stage 
4 level. Her sons were distraught. One of her fellow patients, with whom 
she had grown close, had died five days before. “Thousands of people in 
South Africa die because they cannot access this medicine,” she said.10 
Tobeka Daki died in November, 2016. She never received trastuzumab.11
The story of Tobeka, Roche, and trastuzumab is just one version of a 
story that can be repeated for millions of patients and hundreds of lifesav­
ing medicines across the world. The fact that this particular story is set 
in South Africa is sadly ironic. South Africa was the center of the historic 
struggle to dramatically increase access to HIV/AIDS drugs, a struggle 
described in the conclusion of this book. By challenging patent medicine 
monopolies, South African activists won a victory that ensures that mil­
lions of Tobeka’s countrymen and countrywomen receive affordable anti­
retroviral therapy for HIV/AIDS.
But trastuzumab and many other medicines remain protected by pat­
ents and priced out of reach. Some say that means that medicine activists 
won the HIV/AIDS treatment battle but have lost the broader access-to- 
medicine war. But others say the victory won for HIV/AIDS medicines is 
possible for other kinds of drugs, too. Lillian Dube, also a South African 
woman with breast cancer, was struck by the sight of her fellow patients, 
such as Tobeka, going without the medicine they need. “ I am with young 
women (at our doctor). These are women who are 40, 30, and they have 
small children,” Dube says. “And they have to lose their lives because they 
cannot afford Herceptin. It should not be like that.” 12
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As I show in this book, there are dozens of reasons why Lillian Dube 
is right: it should not be like that. And there are many activists such as 
Lillian Dube who are working to change the system. “Until I die, I’ll be 
fighting this,” she says.15
Ahmed is a little boy, and he is dying. He could be in India or Nigeria or 
Haiti. And he could be dying from pneumonia or diarrhea or measles.
Unlike Tobeka Daki, Ahmed is not one particular person. He cannot 
tell his story to an interviewer. He lays anonymous, engulfed in fever, in 
a hut in a remote village or in a shack in a teeming urban slum. Neither 
his family nor his government could afford to give him the immunizations 
that would have prevented his illness. And they cannot afford the antibi­
otic medicines that would help him survive now.
One out of every five children living in poor countries never receives 
even the most basic package of vaccinations.14 Millions do not have 
access to antibiotic drugs.15 Ahmed is one of 6 million children in low- 
and middle-income countries who will die from an infectious disease this 
year.16 Chances are that his disease is pneumonia because that is the lead­
ing cause of childhood death, in large part because three out of four of the 
world’s children have not been vaccinated against it.’7
There are massive global efforts to expand the vaccination of children, 
such as Ahmed. Gavi, the Vaccine Alliance, leverages funding from the 
Bill and Melinda Gates Foundation and from other public and private 
sources, to immunize millions of children in low-income countries.IX MSF 
delivers nearly 7 million doses of vaccines each year.19 But even these 
efforts were not enough to reach Ahmed, and they will not reach millions 
of other children.
The biggest reason is the cost of the medicines. Dr. Greg Elder, deputy 
director of operations for Medecins Sans Frontieres, says, “The rising 
price of the basic vaccines package means that we can’t afford to protect 
kids living in crisis.”20 That price for a full package of vaccines in 2014 
was sixty-eight times what it was in 2001.21 The most expensive vaccine 
in that package is the pneumococcal vaccine, which generates almost 
$7 billion in sales each year for the pharmaceutical corporations GSK and 
Pfizer, which control the market for the drug.22 In late 2016, a determined 
multiyear advocacy campaign led by MSF finally succeeded in convincing 
the two chief producers of the pneumococcal vaccine to lower the prices
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they charged humanitarian organizations. But advocates cautioned that, 
even after the price drop, the vaccine was still unaffordable in many poor 
countries.25
Tobeka and Ahmed are not isolated examples. The UN World Health 
Organization says that one-third of the world’s population do not have 
access to essential medicines.24 Other UN health officials estimate that 
10 million people die each year because they do not receive the medicines 
that would have saved them.25 That adds up to one person dying every 
three seconds—more people each year than the entire population of New 
York City.
The World Health Organization and others can categorize that number 
by the diseases that are left unchecked. Over a million die each year from 
tuberculosis, and a million-plus more from AIDS, malaria, and hepatitis.26 
Those dying from infectious diseases such as these tend to be younger, like 
Ahmed. But millions more, like Tobeka, die prematurely from untreated 
noncommunicable diseases such as cancer, cardiovascular disease, and 
diabetes.27
The 2015 annual report of the World Health Organization sounds like 
a broken record repeating the same tragic notes:
•  Access to medicines for noncommunicable diseases “ is still very poor in 
many low- and lower-middle income countries.”28
•  A majority of newborns who need hepatitis B immunizations do not get 
them, and most cancer patients who need chemotherapy do not get that 
either.29
• New cancer and hepatitis medicines are enormously effective, but as we 
have learned (chapters 1 and 2), they are “ largely unaffordable while 
under patent, even for many high-income countries.”50
•  For diabetes patients in low-income countries, “essential medicines are 
frequently unavailable or unaffordable.” 51 Same goes for patients in 
need of mental health medicines.52
Even when the lack of medicines is not immediately fatal, it often makes 
survival a miserable experience: billions of people lack access to opioid 
analgesics that can ease the excruciating pain of diseases such as can­
cer.55 Those lucky enough to be able to buy essential medicines often make 
enormous sacrifices to do so. As much as 90 percent of people in low- and
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middle-income countries pay out of pocket for their medicines, making 
it the second-largest family expenditure after food.34 In these countries, 
medicine costs account for nearly half of all health care spending, draw­
ing resources away from hiring doctors and nurses, building clinics, and 
buying other supplies.35
This crisis has not gone unnoticed. Thomas Pogge, a Yale University 
philosopher, calls this poverty-induced suffering and death “the morally 
pre-eminent problem of our age.” 36 The global community has recently 
agreed on a set of Sustainable Development Goals that includes achieving 
universal access to essential medicines.37 In 2015, the UN secretary-general 
convened a High-Level Panel on Access to Medicines, emphasizing the 
urgency of the situation, and the panel issued a report underscoring that 
millions are dying of treatable diseases because they cannot access needed 
medicines.38
But the suffering of Tobeka, Ahmed, and millions of others continues. 
There is no more stark example of our broken medicines system than the 
Ebola epidemic of 2014.
On October 13,2014, Dr. Margaret Chan, the director-general of the World 
Health Organization, provided the keynote address for the sixty-fifth ses­
sion of the WHO Regional Committee for the Western Pacific.39 Most 
conferences like this are highly bureaucratic; the speeches delivered are 
typically long on platitudes and short on drama. But Dr. Chan’s remarks 
were delivered in the midst of the Ebola outbreak in western Africa, an 
outbreak she told the attendees had generated more fear than any event in 
her public health career.
So Dr. Chan took the occasion, and the global media attention to the 
outbreak, as an opportunity to be remarkably frank. Over 11,000 people 
will die from Ebola, she said. “The outbreak spotlights the dangers of the 
world’s growing social and economic inequalities,” she told the attendees. 
“The rich get the best care. The poor are left to die.”40
Dr. Chan was correct. Ebola was a dramatic example of the inequi­
ties in the global health care system, inequities that are particularly stark 
in the field of medicines. The reason Ebola was so frightening and so 
deadly was that no medicines were available to prevent it or to treat it. 
It turns out that promising vaccines to prevent Ebola, and drugs to treat 
it, had been uncovered years before the outbreak. Yet they were allowed 
to languish without further development. “There is a lesson here,” said
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Professor Adrian Hill from Oxford University, who led the Ebola response 
for Britain. “ If we had invested in an Ebola vaccine, had it sitting there 
as the outbreak comes, you could have nipped it in the bud, been able to 
vaccinate the region when it started.”41
So why was the Ebola vaccine not developed? Because pharmaceutical 
corporations saw no prospect of significant profit to be made on the drug. 
The expected need was limited, and those who would benefit were likely 
to be too poor to pay high prices. As far back as 2003, Thomas Geisbert, 
an Ebola researcher, recognized the problem, writing with regret that there 
was “ little commercial interest for developing an Ebola virus vaccine.”42 
After the 2014 outbreak began claiming lives by the thousands, 
Professor Hill labeled the problem in stark terms. “Who makes vac­
cines? Today, commercial vaccine supply is monopolized by four or five 
mega-companies—GSK, Sanofi, Merck, Pfizer—some of the biggest com­
panies in the world,” Hill said. “The problem with that it, even if you’ve 
got a way of making the vaccine, unless there’s a big market, it’s not worth 
the while of a mega-company. . . . There was no business case to make an 
Ebola vaccine for the people who needed it the most.”43
The 11,000 people who died from Ebola are just the latest and most 
visible examples of a core flaw of the for-profit medicine system. Medi­
cines that address the diseases that kill millions of the global poor do 
not present a compelling business case. The U.S. satirical publication The 
Onion put a sadly accurate spin on the tragic situation, publishing a spoof 
article entitled “ Experts: Ebola Vaccine at Least 50 White People Away,”44 
So medicines that would save the lives of the global poor go undevel­
oped. All the while, for-profit corporations rush to market hair-loss cures 
and erectile dysfunction drugs. Such medicines often duplicate others on 
the market and are often frivolous compared to other needed medicines. 
But they still present a good business case, as long as they address the real 
or perceived needs of consumers who can pay high prices.
As she concluded her October 2014 speech, Dr. Chan did not shy away 
from identifying the obvious cause for the 11,000 deaths. “Ebola emerged 
40 years ago. Why are clinicians still empty-handed, with no vaccines and 
no cure? Because Ebola has been, historically, geographically confined to 
poor African nations.
“The R&D [research and development] incentive is virtually non­
existent. A profit-driven industry does not invest in products for markets 
that cannot pay.”45
4Can cer  Patients Face Particula rly  
D eadly  Ba rriers to  M e d ic in e s
In 2013, I was diagnosed with testicular seminoma. Fortunately for me, 
this is a form of cancer that is highly treatable. Even more fortunate for 
me, I could access that treatment. I live in an area where top-level care 
is available, I had good insurance coverage through my employer, and 
I could afford to pay out-of-pocket costs. I am now healthy and have 
every reason to believe the cancer is gone.
Some of you may have had your own experiences of cancer, either as 
a patient yourself or as a friend or family member of someone who has 
had cancer. There are 14 million new cases of cancer diagnosed annually.1
If you or a loved one has faced cancer, you already know about the 
breathtaking cost of the medicines used in its treatment. In 2012, the 
U.S. Food and Drug Administration (FDA) approved twelve new cancer 
drugs. Eleven of them were priced over $100,000 per year per patient.2 
One drug used to treat acute lymphoblastic leukemia, patented by the 
company Amgen, costs $178,000 for the standard course of treatment.3 
Over the past decade, cancer treatment costs have increased 39 percent in
